Dupilumab-Associated Sweet Syndrome

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, presents with sudden onset of skin lesions.
• SS has various subtypes, including idiopathic and drug-induced forms.

Observation:

• A rare case of SS is reported, specifically linked to dupilumab therapy.
• Dupilumab is a monoclonal antibody used for severe eosinophilic asthma and other conditions.

Findings:

• This case highlights dupilumab as a potential, albeit rare, causative agent for Sweet syndrome.
• The histopathologic findings in SS are distinct and aid in diagnosis.

Implications:

• Clinicians must consider dupilumab-induced SS as a potential adverse drug reaction.
• Early identification and management of this condition are essential for patient outcomes.